ATLANTA — An analysis of 160,000 Medicare beneficiaries demonstrated the noninferiority of paclitaxel-coated devices for mortality compared with uncoated devices for the treatment of peripheral artery disease, a speaker reported.
In the analysis, presented at the Society for Cardiovascular Angiography and Interventions Scientific Sessions by Eric A. Secemsky, MD, MSc, RPVI, FACC, FSCAI, FSVM, director of vascular intervention at Beth Israel Deaconess Medical Center, director of vascular research at the Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology and assistant